Navigation Links
Quantel Signs a Distribution Agreement With US-based National Biological

LES ULIS, France, October 14 /PRNewswire-FirstCall/ --

- National Biological to Market Quantel`s 308 Excimer System for Psoriasis and Vitiligo in the United States

Quantel SA (Euronext: QUA), a leading manufacturer of solid state lasers, announced today that it has entered into a Distribution Agreement with National Biological, a leading researcher and developer of light-based systems for medical and cosmetic treatments, for Quantel's 308 Excimer System for monochromatic UVB treatment of psoriasis and vitiligo in the United States.

Monochromatic UVB Therapy

The 308 Excimer System was developed by Quantel Derma, GmbH based in Erlangen, Germany. Its monochromatic light is equivalent to an excimer laser, with comparable clinical results. The 308 Excimer System is portable, efficient and has no consumables.

National Biological's Chief Executive Officer, Ken Oif commented, "The Quantel 308 targeted phototherapy System provides the best solution for the tens of thousands of patients who require localized treatment for psoriasis, vitiligo, and other skin diseases which are responsive to UV light. It is proven to be very effective and extremely easy to use. National Biological is very pleased to be able to provide Dermatologists with the best value of any targeted phototherapy system."

Exclusivity in the United States

The 308 Excimer System will be exclusively marketed by National Biological in the United States. National Biological will provide the Marketing, Sales, Clinical and Service support.

Alain de Salaberry, Quantel's Président Directeur Général said: "Its strong sales organization and its experience with UVB devices make National Biological an ideal partner for the marketing of Quantel's 308 Excimer System."


Founded in 1970, the QUANTEL Group has over the last 10 years established itself as one of the world's leading specialists for scientific (research laboratories, universities), industrial (micromachining, metrics, military) and medical (ophthalmology, dermatology) laser technologies.

ABOUT Nation Biological Corporation, Inc.

National Biological was founded in 1967 by a pharmacist who understood clearly that UV phototherapy provided a safer and more effective treatment than drugs for severe or chronic psoriasis, eczema, vitiligo and other skin conditions. Over the nearly 40 years since then, National Biological has become widely recognized among doctors and patients alike as the world leader in our field, consistently providing innovation, manufacture, and distribution of phototherapy equipment.

    Quantel is listed on NYSE Euronext (compartiment C) FR0000038242 - QUA

    Alain de SALABERRY
    Président Directeur Général
    T : +33-1-69-29-17-00

    Stefan SCHULZE
    CEO Quantel Derma GmbH
    T : +49-9131-9408810

    Mark Friedman
    T : +1-216-831-0600


Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
2. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
3. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
4. Monsanto Company Signs Share Subscription Agreement With Devgen
5. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
6. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
7. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
8. Assay Designs(TM) Announces Additions to the Leadership Team
9. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
10. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
11. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
Post Your Comments:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
Breaking Biology Technology:
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
Breaking Biology News(10 mins):